BioSenic SA Logo

BioSenic SA

Developing ATO and cell therapies for autoimmune diseases and tissue regeneration.

BIOS | BR

Overview

Corporate Details

ISIN(s):
BE0970179827 (+1 more)
LEI:
549300HFIIMTOP1DFR76
Country:
Belgium
Address:
RUE GRANBONPRÉ 11, 1435 MONT-ST-GUIBERT
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BioSenic SA is a biotechnology company focused on developing innovative clinical-stage therapies for autoimmune diseases and regenerative medicine. The company's pipeline is centered on two main platforms: a novel treatment using arsenic trioxide (ATO) to target the underlying causes of autoimmune and inflammatory conditions, and an allogeneic cell therapy platform aimed at tissue repair and organ regeneration. Formerly known as Bone Therapeutics, BioSenic combines its expertise in immunomodulation and cell therapy to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 10:00
Regulatory News Service
BioSenic SA_Proxy EGM_FR_OC draft 2025 11 07(1518280.1).pdf
French 322.9 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
Regulatory News Service
BioSenic SA_Convening notice_2025_FR_2025 11 04(1506176.1).pdf
French 302.6 KB
2025-11-12 10:00
Regulatory News Service
BioSenic SA_ Information on shareholders' rights EGM_FR_2025 11 07(1506226.1).p…
French 152.9 KB
2025-11-12 10:00
Regulatory News Service
BIOS_PR_GMs-2025_FR_2025 11 07(1506246.1).pdf
French 214.9 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-11-12 10:00
Regulatory News Service
BioSenic - Expédition - 30.10.2025.pdf
French 653.3 KB
2025-10-28 07:00
Interim Report
BIOS_H1-PR Report_FR_2025 10 28_final.pdf
French 371.5 KB
2025-09-29 22:00
Pre-Annual General Meeting Information
BioSenic SA_ Information on shareholders' rights GMs_FR_2025 09 29.pdf
French 160.6 KB
2025-09-29 22:00
Share Issue/Capital Change
BioSenic - (FR) Warrant_Plan - 2025 09 29.pdf
French 316.3 KB
2025-09-29 22:00
Management Discussion and Analysis
BioSenic - Rapport de gestion - 20250929-final.pdf
French 616.8 KB
2025-09-29 22:00
Audit Report / Information
BioSenic SA-rapport du commissaire-31 12 2024_signed.pdf
French 1.6 MB
2025-09-29 22:00
Management Discussion and Analysis
BioSenic___Rapport_spécial_CA_(Art_7_228_CSA)_2025_09_29.docx.pdf
French 348.2 KB
2025-09-29 22:00
Annual Report
20250817_Rapport annuel 2024_FR_Final.pdf
French 2.0 MB
2025-09-29 22:00
Proxy Solicitation & Information Statement
BioSenic SA_Proxy AGM_FR_2025 09 29.pdf
French 422.0 KB

Automate Your Workflow. Get a real-time feed of all BioSenic SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioSenic SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioSenic SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-10 POMI SCHNEITER VERONIQUE Board Sell 86,697 1,187.75 EUR
2024-07-09 POMI SCHNEITER VERONIQUE Board Sell 32,308 442.62 EUR
2024-07-08 Rieger Francois Board Sell 5,274,416 77,417.10 EUR
2024-07-05 POMI SCHNEITER VERONIQUE Board Sell 352,341 26,093.82 EUR
2024-07-04 POMI SCHNEITER VERONIQUE Board Sell 410,072 21,276.40 EUR
2024-07-03 POMI SCHNEITER VERONIQUE Board Sell 737,587 15,628.73 EUR
2024-06-24 POMI SCHNEITER VERONIQUE Board Sell 240,192 4,513.45 EUR
2024-03-20 POMI SCHNEITER VERONIQUE Board Sell 438,000 10,687.20 EUR
2024-03-19 POMI SCHNEITER VERONIQUE Board Sell 62,000 1,432.20 EUR
2022-11-03 Stéphenne Jean Board Buy 62,500 9,286.25 EUR

Peer Companies

1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain
IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea
394800
4D Molecular Therapeutics, Inc. Logo
Developing targeted AAV genetic medicines for large market eye, lung, and heart diseases.
United States of America
FDMT
AbCellera Biologics Inc. Logo
An AI-powered platform that discovers and develops antibody therapeutics for pharma partners.
United States of America
ABCL
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea
174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea
203400
Abivax S.A. Logo
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
United States of America
ABVX
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea
298380
Absci Corp Logo
A generative AI drug creation platform for designing and optimizing biologic therapeutics.
United States of America
ABSI
ABVC BIOPHARMA, INC. Logo
Develops plant-based drugs and medical devices for CNS, oncology, and ophthalmic disorders.
United States of America
ABVC

Talk to a Data Expert

Have a question? We'll get back to you promptly.